|Systematic (IUPAC) name|
|N-(4-((4,5-dihydro-2-methylimidazo[4,5-d]benzazepin- 6(1H)-yl)carbonyl)phenyl)- (1,1'-biphenyl)-2-carboxamide|
|(what is this?)|
Conivaptan (YM 087, brand name Vaprisol) is a non-peptide inhibitor of antidiuretic hormone (vasopressin receptor antagonist). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH), and there is some evidence it may be effective in heart failure. It is marketed by Cumberland Pharmaceuticals, Inc.
Conivaptan has not been approved by the FDA for the treatment of decompensated congestive heart failure. However, in theory, vasopressin receptor antagonism would be particularly useful in this setting, and an initial study shows that it has some promise.
- Udelson JE, Smith WB, Hendrix GH et al. (November 2001). "Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure". Circulation 104 (20): 2417–23. doi:10.1161/hc4501.099313. PMID 11705818.
|This hormonal preparation article is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|